MA38354B1 - Préparation contenant un composé de benzothiazolone - Google Patents

Préparation contenant un composé de benzothiazolone

Info

Publication number
MA38354B1
MA38354B1 MA38354A MA38354A MA38354B1 MA 38354 B1 MA38354 B1 MA 38354B1 MA 38354 A MA38354 A MA 38354A MA 38354 A MA38354 A MA 38354A MA 38354 B1 MA38354 B1 MA 38354B1
Authority
MA
Morocco
Prior art keywords
preparation containing
benzothiazolone compound
benzothiazolone
compound
hydroxybenzo
Prior art date
Application number
MA38354A
Other languages
English (en)
Other versions
MA38354A1 (fr
Inventor
Arnaud Grandeury
Nicola Tufilli
Robin Alec Fairhurst
Miloud Achour
Shinji Hatakeyama
Magdalena Koziczak-Holbro
Thomas Ullrich
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA38354A1 publication Critical patent/MA38354A1/fr
Publication of MA38354B1 publication Critical patent/MA38354B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique sous forme dosifiée orale solide contenant un sel de (r)-7-(2-(1-(4-butoxyphényl)-2-méthylpropan-2-ylamino)-1-hydroxyéthyl)-5- hydroxybenzo[d]thiazol-2(3h)-one acétate.
MA38354A 2013-02-28 2014-02-26 Préparation contenant un composé de benzothiazolone MA38354B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361770584P 2013-02-28 2013-02-28
PCT/IB2014/059270 WO2014132205A1 (fr) 2013-02-28 2014-02-26 Préparation contenant un composé de benzothiazolone

Publications (2)

Publication Number Publication Date
MA38354A1 MA38354A1 (fr) 2016-02-29
MA38354B1 true MA38354B1 (fr) 2016-09-30

Family

ID=50238437

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38354A MA38354B1 (fr) 2013-02-28 2014-02-26 Préparation contenant un composé de benzothiazolone

Country Status (31)

Country Link
US (1) US9623012B2 (fr)
EP (1) EP2961391B1 (fr)
JP (2) JP6230626B2 (fr)
KR (1) KR20150120386A (fr)
CN (1) CN104968337A (fr)
AU (1) AU2014222362B2 (fr)
BR (1) BR112015020059A2 (fr)
CA (1) CA2897565A1 (fr)
CL (1) CL2015001940A1 (fr)
CY (1) CY1119202T1 (fr)
DK (1) DK2961391T3 (fr)
EA (1) EA026914B1 (fr)
ES (1) ES2637802T3 (fr)
HK (1) HK1212213A1 (fr)
HR (1) HRP20171177T1 (fr)
HU (1) HUE034353T2 (fr)
IL (1) IL240495A0 (fr)
LT (1) LT2961391T (fr)
MA (1) MA38354B1 (fr)
MX (1) MX2015011290A (fr)
NZ (1) NZ709747A (fr)
PE (1) PE20151608A1 (fr)
PH (1) PH12015501701A1 (fr)
PL (1) PL2961391T3 (fr)
PT (1) PT2961391T (fr)
SA (1) SA515360952B1 (fr)
SG (1) SG11201505544RA (fr)
SI (1) SI2961391T1 (fr)
TN (1) TN2015000310A1 (fr)
WO (1) WO2014132205A1 (fr)
ZA (1) ZA201504863B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
BR112015004127A2 (pt) * 2012-08-30 2017-07-04 Novartis Ag sais de composto benzotiazolona como agonista de beta-2-adrenorreceptor
JP6230626B2 (ja) * 2013-02-28 2017-11-15 ノバルティス アーゲー ベンゾチアゾロン化合物を含む製剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040962A1 (es) 2002-08-09 2005-04-27 Novartis Ag Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto
EP1631260A2 (fr) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a base d'un co-cristal
EP1789394A1 (fr) 2004-05-13 2007-05-30 Boehringer Ingelheim International Gmbh Heterocycles benzocondenses substitues par hydroxy utilises comme beta-agonistes pour le traitement de maladies respiratoires
GB0426164D0 (en) * 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102009003975A1 (de) * 2009-01-07 2010-07-08 Merck Patent Gmbh Benzothiazolonderivate
JO3192B1 (ar) * 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
JP6230626B2 (ja) * 2013-02-28 2017-11-15 ノバルティス アーゲー ベンゾチアゾロン化合物を含む製剤

Also Published As

Publication number Publication date
CA2897565A1 (fr) 2014-09-04
JP2016510020A (ja) 2016-04-04
PE20151608A1 (es) 2015-11-19
PT2961391T (pt) 2017-08-29
US9623012B2 (en) 2017-04-18
BR112015020059A2 (pt) 2017-07-18
SG11201505544RA (en) 2015-09-29
EP2961391B1 (fr) 2017-05-17
SI2961391T1 (sl) 2017-08-31
TN2015000310A1 (en) 2017-01-03
SA515360952B1 (ar) 2016-07-10
US20160000761A1 (en) 2016-01-07
IL240495A0 (en) 2015-09-24
WO2014132205A1 (fr) 2014-09-04
LT2961391T (lt) 2017-07-25
PL2961391T3 (pl) 2017-10-31
HUE034353T2 (en) 2018-02-28
PH12015501701A1 (en) 2015-10-12
CL2015001940A1 (es) 2015-10-30
DK2961391T3 (en) 2017-09-04
EP2961391A1 (fr) 2016-01-06
CY1119202T1 (el) 2018-02-14
CN104968337A (zh) 2015-10-07
MX2015011290A (es) 2015-12-03
KR20150120386A (ko) 2015-10-27
JP2018035186A (ja) 2018-03-08
EA026914B1 (ru) 2017-05-31
EA201591577A1 (ru) 2015-12-30
JP6230626B2 (ja) 2017-11-15
AU2014222362A1 (en) 2015-07-23
HRP20171177T1 (hr) 2017-10-06
AU2014222362B2 (en) 2016-07-21
NZ709747A (en) 2018-04-27
HK1212213A1 (en) 2016-06-10
ZA201504863B (en) 2016-06-29
MA38354A1 (fr) 2016-02-29
ES2637802T3 (es) 2017-10-17

Similar Documents

Publication Publication Date Title
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
EA201891099A1 (ru) 7-(тиазол-5-ил)пирролопиримида в качестве агониста рецептора tlr7
MA39172A1 (fr) Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines
MA37383A1 (fr) Compose heterobicycliques comme inhibiteurs de la beta lactamase
MA41238B1 (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
AU2014270524A8 (en) 2-phenylimidazo [1,2-a]pyrimidines as imaging agents
MX2016006336A (es) Compuestos pirazolopirimidina.
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
SA518390920B1 (ar) مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
AR078722A1 (es) Derivados de 2-oxo-1-pirrolidinila imidazotiadiazol
PH12017502254B1 (en) Pyrazole derivative or pharmaceutically acceptable salt thereof
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
MA39983B1 (fr) Dérivés de carboxamide
MA38354B1 (fr) Préparation contenant un composé de benzothiazolone
IN2014DN05972A (fr)
ZA202006439B (en) Pyrazo-tetrahydroisoquinoline derivatives as dopamine d1 receptor positive modulators
PE20141993A1 (es) Compuestos de benzotiazolona
MA38857B1 (fr) Dérivés de 1-(pipérazin-1-yl)-2-([1,2,4]triazol-1-yl)-éthanone
MA38250A1 (fr) Nouveau dérivés d'hydantoïne pour leurs utilisations dans le traitement de maladies, comme l'osteoporose et la thrombocytopenie
MA41975B1 (fr) Derives d'aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d'alzheimer
BR112020026507A8 (pt) Composto de isotiazolo[5,4-d]pirimidinas como inibidor de irak4
MA37879A1 (fr) Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant
EA201591369A1 (ru) Новые производные пиримидина в качестве ингибиторов фосфодиэстеразы 10 (pde-10)